In addition, significant roles of ANRIL have been found in the development of esophageal squamous cell carcinoma (ESCC) by inhibiting p15 (INK4b) through the transforming growth factor β1 (TGF-β1) signaling pathway [19]. Here, CDKN2B is linked to esophageal squamous cell carcinoma.